CDK4/6i and ICB monotherapy are shown to have overlapping toxicities, particularly hepatic events and interstitial lung disease/pneumonitis, and adverse events were found to be a leading cause of treatment discontinuation. The gene discussed is CDK4; the disease is interstitial lung disease.